{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T16:12:19Z","timestamp":1743005539247,"version":"3.40.3"},"publisher-location":"Cham","reference-count":58,"publisher":"Springer Nature Switzerland","isbn-type":[{"type":"print","value":"9783031571640"},{"type":"electronic","value":"9783031571657"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-031-57165-7_21","type":"book-chapter","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T07:02:03Z","timestamp":1716793323000},"page":"331-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Overview of Potential Antiviral Bioactive Compounds in Poxviruses"],"prefix":"10.1007","author":[{"given":"Sunil","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"21_CR1","doi-asserted-by":"crossref","unstructured":"Andrei G, Snoeck R (2010) Cidofovir activity against poxvirus infections. Viruses 2(12):2803\u20132830","DOI":"10.3390\/v2122803"},{"issue":"1\u20132","key":"21_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0166-3542(02)00196-1","volume":"57","author":"RO Baker","year":"2003","unstructured":"Baker RO, Bray M, Huggins JW (2003) Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 57(1\u20132):13\u201323","journal-title":"Antiviral Res"},{"issue":"4","key":"21_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1128\/mr.47.4.455-509.1983","volume":"47","author":"AM Behbehani","year":"1983","unstructured":"Behbehani AM (1983) The smallpox story: life and death of an old disease. Microbiol Rev 47(4):455\u2013509","journal-title":"Microbiol Rev"},{"issue":"3","key":"21_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2022.104117","volume":"51","author":"P Berche","year":"2022","unstructured":"Berche P (2022) Life and death of smallpox. La Presse M\u00e9d 51(3):104117","journal-title":"La Presse M\u00e9d"},{"issue":"9311","key":"21_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(02)08115-1","volume":"359","author":"J Bradbury","year":"2002","unstructured":"Bradbury J (2002) Orally available cidofovir derivative active against smallpox. Lancet 359(9311):1041","journal-title":"Lancet"},{"issue":"8","key":"21_CR6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJM199808203390811","volume":"339","author":"JG Breman","year":"1998","unstructured":"Breman JG, Henderson DA (1998) Poxvirus dilemmas\u2014monkeypox, smallpox, and biologic terrorism. N Engl J Med 339(8):556\u2013559","journal-title":"N Engl J Med"},{"issue":"11","key":"21_CR7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1128\/aac.00841-22","volume":"66","author":"LE Brown","year":"2022","unstructured":"Brown LE, Seitz S, Kondas AV, Marcyk PT, Filone CM, Hossain MM, Schaus SE, Olson VA, Connor JH (2022) Identification of small molecules with improved potency against orthopoxviruses from vaccinia to smallpox. Antimicrob Agents Chemother 66(11):822\u2013841","journal-title":"Antimicrob Agents Chemother"},{"key":"21_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdc.2022.100873","volume":"39","author":"KK Burranboina","year":"2022","unstructured":"Burranboina KK, Kumar KM, Reddy GM, Yogisharadhya R, Prashantha CN, Dhulappa A (2022) GC-MS analysis, molecular Docking and pharmacokinetic studies of various bioactive compounds from methanolic leaf extracts of Leucas aspera (L.) against the anti-Capripox viral activity. Chem Data Collect 39:100873","journal-title":"Chem Data Collect"},{"issue":"12","key":"21_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0966-842X(94)90652-1","volume":"2","author":"DM Coen","year":"1994","unstructured":"Coen DM (1994) Acyclovir-resistant, pathogenic herpes viruses. Trends Microbiol 2(12):481\u2013485","journal-title":"Trends Microbiol"},{"key":"21_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","volume":"147","author":"E De Clercq","year":"2006","unstructured":"De Clercq E, Field HJ (2006) Antiviral prodrugs\u2014the development of successful prodrug strategies for antiviral chemotherapy. Br J Pharmacol 147:1\u201311","journal-title":"Br J Pharmacol"},{"issue":"2","key":"21_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/CMR.14.2.382-397.2001","volume":"14","author":"E De Clercq","year":"2001","unstructured":"De Clercq E (2001) Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 14(2):382\u2013397","journal-title":"Clin Microbiol Rev"},{"key":"21_CR12","doi-asserted-by":"crossref","unstructured":"De Clercq E (2002a) Cidofovir in the treatment of poxvirus infections. Antiviral Res 55(1):1\u201313a","DOI":"10.1016\/S0166-3542(02)00008-6"},{"key":"21_CR15","doi-asserted-by":"crossref","unstructured":"De Clercq E (2002b) Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci 23(10):456\u2013458","DOI":"10.1016\/S0165-6147(02)02091-6"},{"issue":"7","key":"21_CR13","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.bcp.2006.09.014","volume":"73","author":"E De Clercq","year":"2007","unstructured":"De Clercq E (2007) Acyclic nucleoside phosphonates: past, present and future: bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 73(7):911\u2013922","journal-title":"Biochem Pharmacol"},{"key":"21_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2022.102528","volume":"52","author":"E De Clercq","year":"2023","unstructured":"De Clercq E, Jiang Y, Li G (2023) Therapeutic strategies for human poxvirus infections: Monkeypox (pox), smallpox, molluscipox, and orf. Travel Med Infect Dis 52:102528","journal-title":"Travel Med Infect Dis"},{"issue":"22","key":"21_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJM199111283252203","volume":"325","author":"LM Dunkle","year":"1991","unstructured":"Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, Gershon AA, Levy ML, Hayden GF, McGuirt PV, Harris J (1991) A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 325(22):1539\u20131544","journal-title":"N Engl J Med"},{"issue":"5","key":"21_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0168-8278(96)80225-X","volume":"25","author":"G Dusheiko","year":"1996","unstructured":"Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G (1996) Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 25(5):591\u2013598","journal-title":"J Hepatol"},{"issue":"1","key":"21_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0002-9343(82)90055-9","volume":"73","author":"GB Elion","year":"1982","unstructured":"Elion GB (1982) Mechanism of action and selectivity of acyclovir. Am J Med 73(1):7\u201313","journal-title":"Am J Med"},{"key":"21_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/jac\/12.suppl_B.9","volume":"12","author":"GB Elion","year":"1983","unstructured":"Elion GB (1983) The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother 12:9\u201317","journal-title":"J Antimicrob Chemother"},{"key":"21_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jmv.1890410503","volume":"1","author":"GB Elion","year":"1993","unstructured":"Elion GB (1993) Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol 1:2\u20136","journal-title":"J Med Virol"},{"key":"21_CR21","doi-asserted-by":"crossref","unstructured":"Follett EAC, Pennington TH (1973) The mode of action of rifamycins and related compounds on poxvirus. In: Advances in virus research, vol 18. Academic Press, pp 105\u2013142","DOI":"10.1016\/S0065-3527(08)60820-9"},{"issue":"2","key":"21_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1128\/AAC.30.2.201","volume":"30","author":"BE Gilbert","year":"1986","unstructured":"Gilbert BE, Knight V (1986) Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 30(2):201\u2013205","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"21_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.virs.2022.07.006","volume":"37","author":"Q Gong","year":"2022","unstructured":"Gong Q, Wang C, Chuai X, Chiu S (2022) Monkeypox virus: a re-emergent threat to humans. Virol Sin 37(4):477\u2013482","journal-title":"Virol Sin"},{"issue":"1","key":"21_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/rmv.483","volume":"16","author":"JD Graci","year":"2006","unstructured":"Graci JD, Cameron CE (2006) Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16(1):37\u201348","journal-title":"Rev Med Virol"},{"issue":"31","key":"21_CR25","doi-asserted-by":"publisher","first-page":"11178","DOI":"10.1073\/pnas.0403600101","volume":"101","author":"SC Harrison","year":"2004","unstructured":"Harrison SC, Alberts B, Ehrenfeld E, Enquist L, Fineberg H, McKnight SL, Moss B, O\u2019Donnell M, Ploegh H, Schmid SL, Walter KP (2004) Discovery of antivirals against smallpox. Proc Natl Acad Sci 101(31):11178\u201311192","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"21_CR26","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.imbio.2010.11.001","volume":"216","author":"HP Huemer","year":"2011","unstructured":"Huemer HP, Lassnig C, Bernhard D, Sturm S, Nowotny N, Kitchen M, Pavlic M (2011) Cannabinoids lead to enhanced virulence of the smallpox vaccine (vaccinia) virus. Immunobiology 216(6):670\u2013677","journal-title":"Immunobiology"},{"key":"21_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.vaccine.2009.07.103","volume":"27","author":"RB Kennedy","year":"2009","unstructured":"Kennedy RB, Ovsyannikova I, Poland GA (2009) Smallpox vaccines for biodefense. Vaccine 27:73\u201379","journal-title":"Vaccine"},{"issue":"1\u20132","key":"21_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0166-3542(02)00198-5","volume":"57","author":"ER Kern","year":"2003","unstructured":"Kern ER (2003) In vitro activity of potential anti-poxvirus agents. Antiviral Res 57(1\u20132):35\u201340","journal-title":"Antiviral Res"},{"issue":"4","key":"21_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","volume":"46","author":"ER Kern","year":"2002","unstructured":"Kern ER, Hartline C, Harden E, Keith K, Rodriguez N, Beadle JR, Hostetler KY (2002) Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 46(4):991\u2013995","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"21_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1196\/annals.1352.014","volume":"1056","author":"GJ Kotwal","year":"2005","unstructured":"Kotwal GJ, Kaczmarek JN, Leivers S, Ghebremariam YT, Kulkarni AP, Bauer G, De Beer C, Preiser W, Mohamed AR (2005) Anti-HIV, anti-poxvirus, and anti-SARS activity of a nontoxic, acidic plant extract from the Trifollium species secomet-V\/anti-vac suggests that it contains a novel broad-spectrum antiviral. Ann N Y Acad Sci 1056(1):293\u2013302","journal-title":"Ann N Y Acad Sci"},{"key":"21_CR31","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00003088-198308030-00001","volume":"8","author":"OL Laskin","year":"1983","unstructured":"Laskin OL (1983) Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 8:187\u2013201","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"21_CR32","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","volume":"49","author":"WC Magee","year":"2005","unstructured":"Magee WC, Hostetler KY, Evans DH (2005) Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49(8):3153\u20133162","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"21_CR33","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/wrna.1515","volume":"10","author":"N Meade","year":"2019","unstructured":"Meade N, DiGiuseppe S, Walsh D (2019) Translational control during poxvirus infection. Wiley Interdisc Rev RNA 10(2):1515","journal-title":"Wiley Interdisc Rev RNA"},{"key":"21_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.antiviral.2019.06.005","volume":"168","author":"M Merchlinsky","year":"2019","unstructured":"Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C, Petersen B, Hallberg M (2019) The development and approval of tecoviromat (TPOXX\u00ae), the first antiviral against smallpox. Antiviral Res 168:168\u2013174","journal-title":"Antiviral Res"},{"issue":"4","key":"21_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/computation11040084","volume":"11","author":"F Mollaamin","year":"2023","unstructured":"Mollaamin F (2023) Computational methods in the drug delivery of carbon nanocarriers onto several compounds in sarraceniaceae medicinal plant as Monkeypox therapy. Computation 11(4):84","journal-title":"Computation"},{"issue":"17","key":"21_CR36","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.3390\/molecules27175393","volume":"27","author":"AL Morales-Ubaldo","year":"2022","unstructured":"Morales-Ubaldo AL, Rivero-Perez N, Valladares-Carranza B, Madariaga-Navarrete A, Higuera-Piedrahita RI, Delgadillo-Ruiz L, Ba\u00f1uelos-Valenzuela R, Zaragoza-Bastida A (2022) Phytochemical compounds and pharmacological properties of Larrea tridentata. Molecules 27(17):5393","journal-title":"Molecules"},{"issue":"2","key":"21_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.virusres.2007.09.008","volume":"131","author":"M Mukhtar","year":"2008","unstructured":"Mukhtar M, Arshad M, Ahmad M, Pomerantz RJ, Wigdahl B, Parveen Z (2008) Antiviral potentials of medicinal plants. Virus Res 131(2):111\u2013120","journal-title":"Virus Res"},{"issue":"1\u20132","key":"21_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0166-3542(02)00197-3","volume":"57","author":"J Neyts","year":"2003","unstructured":"Neyts J, De Clercq E (2003) Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res 57(1\u20132):25\u201333","journal-title":"Antiviral Res"},{"issue":"1","key":"21_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.antiviral.2008.03.007","volume":"80","author":"HH Nollens","year":"2008","unstructured":"Nollens HH, Gulland FM, Jacobson ER, Hernandez JA, Klein PA, Walsh MT, Condit RC (2008) In vitro susceptibility of sea lion poxvirus to cidofovir. Antiviral Res 80(1):77\u201380","journal-title":"Antiviral Res"},{"issue":"3","key":"21_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2217\/fvl-2018-0166","volume":"14","author":"K Nystr\u00f6m","year":"2019","unstructured":"Nystr\u00f6m K, Waldenstr\u00f6m J, Tang KW, Lagging M (2019) Ribavirin: pharmacology, multiple modes of action and possible future perspectives. Futur Virol 14(3):153\u2013160","journal-title":"Futur Virol"},{"key":"21_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/00003495-198937030-00002","volume":"37","author":"JJ O\u2019Brien","year":"1989","unstructured":"O\u2019Brien JJ, Campoli-Richards DM (1989) Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties, and therapeutic efficacy. Drugs 37:233\u2013309","journal-title":"Drugs"},{"issue":"6","key":"21_CR42","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","volume":"118","author":"J Parrino","year":"2006","unstructured":"Parrino J, Graham BS (2006) Smallpox vaccines: past, present, and future. J Allergy Clin Immunol 118(6):1320\u20131326","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"21_CR43","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/clinids\/12.6.1139","volume":"12","author":"JL Patterson","year":"1990","unstructured":"Patterson JL, Fernandez-Larsson R (1990) Molecular mechanisms of action of ribavirin. Rev Infect Dis 12(6):1139\u20131146","journal-title":"Rev Infect Dis"},{"issue":"4","key":"21_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/13102818.2007.10817486","volume":"21","author":"S Paunovic","year":"2007","unstructured":"Paunovic S, Ruzic D, Vujovic T, Milenkovic S, Jevremovic D (2007) In vitro production of Plum pox virus-free plums by chemotherapy with ribavirin. Biotechnol Biotechnol Equip 21(4):417\u2013421","journal-title":"Biotechnol Biotechnol Equip"},{"issue":"2","key":"21_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2020.102093","volume":"33","author":"KM Ramalho","year":"2021","unstructured":"Ramalho KM, Cunha SR, Gon\u00e7alves F, Escudeiro GS, Steiner-Oliveira C, Horliana A, de Paula EC (2021) Photodynamic therapy and acyclovir in the treatment of recurrent herpes labialis: a controlled randomized clinical trial. Photodiagn Photodyn Ther 33(2):102093","journal-title":"Photodiagn Photodyn Ther"},{"key":"21_CR46","doi-asserted-by":"crossref","unstructured":"Remichkova M (2010) Poxviruses: smallpox vaccine, its complications, and chemotherapy. Virus Adapt Treat 2:41\u201346","DOI":"10.2147\/VAAT.S8563"},{"issue":"6","key":"21_CR47","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3201\/eid0706.010602","volume":"7","author":"SR Rosenthal","year":"2001","unstructured":"Rosenthal SR, Merchlinsky M, Kleppinger C, Goldenthal KL (2001) Developing new smallpox vaccines. Emerg Infect Dis 7(6):920","journal-title":"Emerg Infect Dis"},{"issue":"26","key":"21_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115322","volume":"206","author":"HH Schalkwijk","year":"2022","unstructured":"Schalkwijk HH, Snoeck R, Andrei G (2022) Acyclovir resistance in herpes simplex viruses: prevalence and therapeutic alternatives. Biochem Pharmacol 206(26):115322","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"21_CR49","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/14787210.2021.1917992","volume":"19","author":"K Shiraki","year":"2021","unstructured":"Shiraki K, Takemoto M, Daikoku T (2021) Emergence of varicella-zoster virus resistance to acyclovir: epidemiology, prevention, and treatment. Expert Rev Anti Infect Ther 19(11):1415\u20131425","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"21_CR50","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/095632020101200602","volume":"12","author":"DF Smee","year":"2001","unstructured":"Smee DF, Bray M, Huggins JW (2001) Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antiviral Chem Chemother 12(6):327\u2013335","journal-title":"Antiviral Chem Chemother"},{"key":"21_CR51","doi-asserted-by":"crossref","unstructured":"Sudarmaji N, Kifli N, Hermansyah A, Yeoh SF, Goh BH, Ming LC (2022) Prevention and treatment of monkeypox: a systematic review of preclinical studies. Viruses 14(11), 2496, 2\u201329","DOI":"10.3390\/v14112496"},{"issue":"5","key":"21_CR52","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/095632020101200501","volume":"12","author":"RC Tam","year":"2001","unstructured":"Tam RC, Lau JY, Hong Z (2001) Mechanisms of action of ribavirin in antiviral therapies. Antiviral Chem Chemother 12(5):261\u2013272","journal-title":"Antiviral Chem Chemother"},{"issue":"3","key":"21_CR53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/1469-0691.12536","volume":"20","author":"C Th\u00e8ves","year":"2014","unstructured":"Th\u00e8ves C, Biagini P, Crub\u00e9zy E (2014) The rediscovery of smallpox. Clin Microbiol Infect 20(3):210\u2013218","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"21_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106114","volume":"56","author":"S Tong","year":"2020","unstructured":"Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, Jiang J (2020) Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents 56(3):106114","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"21_CR55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/stem.5530080303","volume":"8","author":"G Tricot","year":"1990","unstructured":"Tricot G, Jayaram HN, Weber G, Hoffman R (1990) Tiazofurin: biological effects and clinical uses. Int J Cell Cloning 8(3):161\u2013170","journal-title":"Int J Cell Cloning"},{"key":"21_CR01","unstructured":"Weber G, Prajda N, Abonyi M, Look KY, Tricot G (1996) Tiazofurin: molecular and clinical action. Anticancer Res 16(6A):3313\u20133322"},{"issue":"11","key":"21_CR56","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1056\/NEJM199209103271108","volume":"327","author":"RJ Whitley","year":"1992","unstructured":"Whitley RJ, Gnann JW Jr (1992) Acyclovir: a decade later. N Engl J Med 327(11):782\u2013789","journal-title":"N Engl J Med"},{"key":"21_CR57","unstructured":"World Health Organization (WHO) https:\/\/www.who.int\/news-room\/factsheets\/detail\/monkeypox"}],"container-title":["Advances in Experimental Medicine and Biology","Poxviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-57165-7_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T07:07:30Z","timestamp":1716793650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-57165-7_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031571640","9783031571657"],"references-count":58,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-57165-7_21","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"28 May 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}